Status:

ACTIVE_NOT_RECRUITING

Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs

Lead Sponsor:

Kirby Institute

Conditions:

Hepatitis C

Hepatitis C, Chronic

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This project aims to evaluate two strategies of Hepatitis C virus (HCV) testing compared to standard of care among people who inject drugs at needle and syringe program (NSP) services in Australia, to...

Detailed Description

The TEMPO study will compare dried blood spot testing and point-of-care HCV RNA testing to standard of care as strategies to enhance HCV treatment uptake among people with HCV and recent injecting dru...

Eligibility Criteria

Inclusion

  • Inclusion criteria for participants:
  • Attendees of the NSP service are eligible for inclusion if the following criteria are met:
  • Provided written informed consent
  • ≥ 18 years of age
  • Recent injecting drug use - defined as self-reported use within the previous six months.
  • Exclusion criteria for participants:
  • a. Is unable or unwilling to provide informed consent or abide by the requirements of the study.

Exclusion

    Key Trial Info

    Start Date :

    July 27 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 31 2026

    Estimated Enrollment :

    2700 Patients enrolled

    Trial Details

    Trial ID

    NCT04014179

    Start Date

    July 27 2022

    End Date

    July 31 2026

    Last Update

    July 17 2025

    Active Locations (17)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (17 locations)

    1

    Bankstown NSP

    Bankstown, New South Wales, Australia, 2200

    2

    WSLHD Drug Health - Blacktown NSP

    Blacktown, New South Wales, Australia, 2148

    3

    Coffs Harbour Primary NSP

    Coffs Harbour, New South Wales, Australia, 2450

    4

    Gosford NSP

    Gosford, New South Wales, Australia, 2250